These findings are consistent with published data about the safety of the aforementioned therapies [21,35,36,37], particularly referring to the association between anti-TNF treatments, and both the reduced odds of hospitalization and the lower rate of complications during COVID-19, since also in our cohort the most used biologic drugs were anti-TNFs (24/37). This evidence concerns the gene TNF and COVID-19.